002038 双鹭药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.5097.3964.3498.2827.460
总资产报酬率 ROA (%)0.4786.8574.0297.6376.869
投入资产回报率 ROIC (%)0.5037.2774.2908.1907.274

边际利润分析
销售毛利率 (%)77.07781.56085.05484.88985.313
营业利润率 (%)4.71546.92625.07437.66437.105
息税前利润/营业总收入 (%)3.58444.19423.27636.33636.197
净利润/营业总收入 (%)7.34240.74821.74334.68232.483

收益指标分析
经营活动净收益/利润总额(%)705.35954.32773.45855.68940.166
价值变动净收益/利润总额(%)-561.69551.51038.53545.65157.987
营业外收支净额/利润总额(%)-0.016-2.791-1.5290.064-0.025

偿债能力分析
流动比率 (X)13.5327.0726.9167.0717.008
速动比率 (X)12.5346.6856.4436.6876.652
资产负债率 (%)4.1447.4506.7507.5387.602
带息债务/全部投入资本 (%)-0.5100.091-0.435-0.813--
股东权益/带息债务 (%)-19,473.266108,232.141-22,658.472-12,144.326-10,945.783
股东权益/负债合计 (%)2,309.9811,240.1781,378.7341,223.1881,213.041
利息保障倍数 (X)-3.173-30.320-16.394-26.884-40.259

营运能力分析
应收账款周转天数 (天)81.38180.077102.567117.3060.000
存货周转天数 (天)322.969269.611300.065232.2520.000